GlassScriptPhysician profile
Richard Torrey
NPI 1144315342
$1,912.07
in general payments reported to CMS, 2019-2025
21 companies · $15.88 in 2025
The $15.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $319 · 2021: $76.67 · 2022: $184 · 2023: $202 · 2024: $287 · 2025: $15.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.30 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $372.28 | 2019-2024 | |
| Lilly USA, LLC | $323.48 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $87.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.84 | 2019-2020 | |
| Amarin Pharma, INC. | $52.07 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.95 | 2022 | |
| Bausch Health US, LLC | $41.57 | 2019 | |
| Merck Sharp & Dohme LLC | $35.97 | 2019 | |
| Glaxosmithkline, LLC. | $25.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $18.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $15.88 | 2025 | Sx-One Microknife |
| Amgen INC. | $15.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.21 | 2019 | |
| Genentech USA, INC. | $12.55 | 2020 | |
| Allergan, INC. | $12.10 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Torrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.